New York Times Co vs Teladoc Health Inc — how do they compare? New York Times Co trades at $66.32 (market cap $10.74B), while Teladoc Health Inc trades at $5.77 (market cap $1.01B). The key difference: New York Times Co is far larger — about 10.6× Teladoc Health Inc's market cap, and New York Times Co pays a 1.38% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 81 Days and Teladoc Health Inc for 39 Days on average.
| NYT | TDOC | |
|---|---|---|
Market Cap | $10.74B | $1.01B |
Volume | 2,096,352 | 4,668,477 |
Sector | Media | Health |
52-Week High | $85.86 | $9.72 |
52-Week Low | $54.66 | $4.47 |
Typical Hold Time | 81 Days | 39 Days |
Enterprise Value | $10.14B | $1.27B |
Dividend Yield | 1.38% | — |
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $66.60, up 2.62% today, reflecting strong momentum after three consecutive quarterly earnings beats. Revenue and net income have grown steadily from 2022 to 2025, with profit margins expanding to 12.17%. The stock shows a bullish technical signal overall, supported by positive cash flow trends and a declared quarterly dividend of $0.23 per share. However, a recent shareholder lawsuit alleging reporting bias introduces reputational risk.
Outlook remains positive given consistent earnings outperformance and a consensus price target of $84.00, implying significant upside. Key risks include the ongoing lawsuit, competitive pressures in digital media, and potential volatility from the AI copyright dispute with OpenAI. The company's solid fundamentals and analyst support suggest resilience, but investors should weigh legal and market challenges.
TDOC trades at $5.54, down 0.36% on the day, with a bearish technical signal and mixed earnings history. The company reported revenue of $2.53B in 2025 but a net loss of $200.32M, reflecting ongoing profitability challenges. Analyst consensus is a 'Hold' with a $8.83 price target, indicating potential upside. Recent news includes a CFO transition and legal investigations, adding to investor uncertainty.
The outlook remains cautious due to persistent losses and competitive pressures, though valuation metrics like P/S of 0.4 and EV/EBITDA of 5.89 suggest the stock is undervalued. Key risks include weak cash flow trends and BetterHelp segment volatility. Upside depends on execution in integrated care and cost management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →